PRASUGREL - Generic Drug Details
✉ Email this page to a colleague
Summary for PRASUGREL
US Patents: | 0 |
Tradenames: | 3 |
Applicants: | 10 |
NDAs: | 10 |
Drug Master File Entries: | 19 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 127 |
Clinical Trials: | 225 |
Patent Applications: | 186 |
Drug Prices: | Drug price trends for PRASUGREL |
What excipients (inactive ingredients) are in PRASUGREL? | PRASUGREL excipients list |
DailyMed Link: | PRASUGREL at DailyMed |
Recent Clinical Trials for PRASUGREL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Giampiero Vizzari | Phase 3 |
Giorgio Quadri | Phase 3 |
Ferdinando Varbella | Phase 3 |
US Patents and Regulatory Information for PRASUGREL
EU/EMA Drug Approvals for PRASUGREL
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Mylan Pharmaceuticals Limited | Prasugrel Mylan | prasugrel | EMEA/H/C/004644 Prasugrel Mylan, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI). |
Authorised | yes | no | no | 2018-05-15 | |
Substipharm | Efient | prasugrel | EMEA/H/C/000984 Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST-segment-elevation myocardial infarction [UA / NSTEMI] or ST-segment-elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI). |
Authorised | no | no | no | 2009-02-24 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |